Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Colchicine in the Management of Acute Coronary Syndrome: A Meta-analysis

Colchicine in the Management of Acute Coronary Syndrome: A Meta-analysis IntroductionColchicine, thought to exert its effect via reduction of inflammation, has recently been studied in patients following acute coronary syndromes (ACS). We performed a meta-analysis of all available randomized controlled trials (RCTs) in this high-risk cohort, evaluating efficacy and safety.MethodsMEDLINE, PubMed, EMBASE, clinical trial registries, and select conference proceedings were searched for RCTs comparing colchicine to placebo in patients following ACS. The primary outcome was trial-defined major adverse cardiovascular events (MACE). Secondary endpoints included stroke, myocardial infarction (MI), all-cause and cardiovascular death, and urgent revascularization. Analysis was performed at the longest available clinical follow-up.ResultsTwo RCTs with a pooled sample size of 5540 patients with 2778 (50.1%) receiving colchicine and 2762 (49.9%) placebo were included. In order to maximize consistency, composite efficacy endpoints between trials were modified. Compared to placebo, patients receiving colchicine had reduction in study-defined composite endpoint (5.5% vs. 7.6%) OR 0.67 (95% CI 0.46–0.98, p = 0.04, I2 = 46%). Similarly, there was a significant reduction in cerebrovascular accidents (OR 0.31, 95% CI 0.14–0.69, p = 0.004, I2 = 0%) and repeat revascularization OR 0.36 (95% CI 0.14–0.90, p = 0.03, I2 = 54%). There was no difference between cardiovascular death (OR 0.92, 95% CI 0.52–1.62, p = 0.78, I2 = 0%), non-cardiovascular death OR 1.27 (95% CI 0.72–2.24, p = 0.41, I2 = 0%), MI at longest available follow-up OR 0.89 (95% CI 0.67–1.17, p = 0.39, I2 = 0%) or resuscitated cardiac arrest OR 0.88 (95% CI 0.32–2.43, p = 0.81, I2 = 0%) in those receiving colchicine.ConclusionsThese data suggest colchicine, in addition to guideline-directed medical therapy following acute coronary syndrome reduces MACE, cerebrovascular accidents, and rates of urgent revascularization at 2 years of follow-up. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cardiology and Therapy Springer Journals

Colchicine in the Management of Acute Coronary Syndrome: A Meta-analysis

Download PDF
11 pages

Loading next page...
 
/lp/springer-journals/colchicine-in-the-management-of-acute-coronary-syndrome-a-meta-t5s4xdYL7M
Publisher
Springer Journals
Copyright
Copyright © The Author(s) 2023. corrected publication 2023
ISSN
2193-8261
eISSN
2193-6544
DOI
10.1007/s40119-022-00298-y
Publisher site
See Article on Publisher Site

Abstract

IntroductionColchicine, thought to exert its effect via reduction of inflammation, has recently been studied in patients following acute coronary syndromes (ACS). We performed a meta-analysis of all available randomized controlled trials (RCTs) in this high-risk cohort, evaluating efficacy and safety.MethodsMEDLINE, PubMed, EMBASE, clinical trial registries, and select conference proceedings were searched for RCTs comparing colchicine to placebo in patients following ACS. The primary outcome was trial-defined major adverse cardiovascular events (MACE). Secondary endpoints included stroke, myocardial infarction (MI), all-cause and cardiovascular death, and urgent revascularization. Analysis was performed at the longest available clinical follow-up.ResultsTwo RCTs with a pooled sample size of 5540 patients with 2778 (50.1%) receiving colchicine and 2762 (49.9%) placebo were included. In order to maximize consistency, composite efficacy endpoints between trials were modified. Compared to placebo, patients receiving colchicine had reduction in study-defined composite endpoint (5.5% vs. 7.6%) OR 0.67 (95% CI 0.46–0.98, p = 0.04, I2 = 46%). Similarly, there was a significant reduction in cerebrovascular accidents (OR 0.31, 95% CI 0.14–0.69, p = 0.004, I2 = 0%) and repeat revascularization OR 0.36 (95% CI 0.14–0.90, p = 0.03, I2 = 54%). There was no difference between cardiovascular death (OR 0.92, 95% CI 0.52–1.62, p = 0.78, I2 = 0%), non-cardiovascular death OR 1.27 (95% CI 0.72–2.24, p = 0.41, I2 = 0%), MI at longest available follow-up OR 0.89 (95% CI 0.67–1.17, p = 0.39, I2 = 0%) or resuscitated cardiac arrest OR 0.88 (95% CI 0.32–2.43, p = 0.81, I2 = 0%) in those receiving colchicine.ConclusionsThese data suggest colchicine, in addition to guideline-directed medical therapy following acute coronary syndrome reduces MACE, cerebrovascular accidents, and rates of urgent revascularization at 2 years of follow-up.

Journal

Cardiology and Therapy – Springer Journals

Published: Mar 1, 2023

Keywords: Colchicine; Acute coronary syndrome; Myocardial infarction; MACE

References

  • Global perspective on acute coronary syndrome: a burden on the young and poor
    Vedanthan, R; Seligman, B; Fuster, V
  • 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
    Collet, JP; Thiele, H; Barbato, E; Barthelemy, O; Bauersachs, J; Bhatt, DL
  • 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons
    Fihn, SD; Gardin, JM; Abrams, J; Berra, K; Blankenship, JC; Dallas, AP
  • 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
    Ibanez, B; James, S; Agewall, S; Antunes, MJ; Bucciarelli-Ducci, C; Bueno, H
  • Inflammation and cardiovascular disease: from pathogenesis to therapeutic target
    Golia, E; Limongelli, G; Natale, F; Fimiani, F; Maddaloni, V; Pariggiano, I
  • The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation
    Martinez, GJ; Celermajer, DS; Patel, S
  • Efficacy and safety of low-dose colchicine after myocardial infarction
    Tardif, JC; Kouz, S; Waters, DD; Bertrand, OF; Diaz, R; Maggioni, AP
  • Colchicine in patients with acute coronary syndrome: the Australian cops randomized clinical trial
    Tong, DC; Quinn, S; Nasis, A; Hiew, C; Roberts-Thomson, P; Adams, H
  • Anti-inflammatory treatment with colchicine in acute myocardial infarction: a pilot study
    Deftereos, S; Giannopoulos, G; Angelidis, C; Alexopoulos, N; Filippatos, G; Papoutsidakis, N
  • The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
    Liberati, A; Altman, DG; Tetzlaff, J; Mulrow, C; Gotzsche, PC; Ioannidis, JP
  • The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
    Higgins, JP; Altman, DG; Gotzsche, PC; Juni, P; Moher, D; Oxman, AD
  • Measuring inconsistency in meta-analyses
    Higgins, JP; Thompson, SG; Deeks, JJ; Altman, DG
  • Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials
    Stewart, S; Yang, KCK; Atkins, K; Dalbeth, N; Robinson, PC
  • NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
    Duewell, P; Kono, H; Rayner, KJ; Sirois, CM; Vladimer, G; Bauernfeind, FG
  • Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation
    Rajamaki, K; Lappalainen, J; Oorni, K; Valimaki, E; Matikainen, S; Kovanen, PT
  • Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group
    Franzosi, MG
  • Effects of early and late administration of angiotensin-converting enzyme inhibitors on mortality after myocardial infarction
    Rodrigues, EJ; Eisenberg, MJ; Pilote, L
  • Early intravenous beta-blockers in patients with acute coronary syndrome–a meta-analysis of randomized trials
    Chatterjee, S; Chaudhuri, D; Vedanthan, R; Fuster, V; Ibanez, B; Bangalore, S
  • Beta-blockers for suspected or diagnosed acute myocardial infarction
    Safi, S; Sethi, NJ; Nielsen, EE; Feinberg, J; Jakobsen, JC; Gluud, C
  • Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction
    Yusuf, S; Wittes, J; Friedman, L
  • beta blockade after myocardial infarction: systematic review and meta regression analysis
    Freemantle, N; Cleland, J; Young, P; Mason, J; Harrison, J
  • Clinical outcomes with beta-blockers for myocardial infarction: a meta-analysis of randomized trials
    Bangalore, S; Makani, H; Radford, M; Thakur, K; Toklu, B; Katz, SD
  • Design and rationale of the Danish trial of beta-blocker treatment after myocardial infarction without reduced ejection fraction: study protocol for a randomized controlled trial
    Kristensen, AMD; Bovin, A; Zwisler, AD; Cerquira, C; Torp-Pedersen, C; Botker, HE